Patents by Inventor Christopher Wendler

Christopher Wendler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
    Publication number: 20230295319
    Abstract: Aspects of the disclosure relate to chimeric antigen receptors (CARs) comprising an antigen binding domain (e.g., anti-TSHR), transmembrane domain (e.g., CD28), and a cytoplasmic domain (e.g., CD27, CD-137, etc.) and a safety mechanism comprising an inducible apoptosis trigger. In some aspects, the disclosure relates to use of the CARs in T cells, compositions, kits and methods for the treatment of thyroid cancers.
    Type: Application
    Filed: March 6, 2023
    Publication date: September 21, 2023
    Applicant: University of Florida Research Foundation, Incorporated
    Inventors: Scott A. Rivkees, Christopher Wendler, Lung-Ji Chang
  • Chimeric antigen receptors and uses thereof
    Patent number: 11634498
    Abstract: Aspects of the disclosure relate to chimeric antigen receptors (CARs) comprising an antigen binding domain (e.g., anti-TSHR), transmembrane domain (e.g., CD28), and a cytoplasmic domain (e.g., CD27, CD-137, etc.) and a safety mechanism comprising an inducible apoptosis trigger. In some aspects, the disclosure relates to use of the CARs in T cells, compositions, kits and methods for the treatment of thyroid cancers.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: April 25, 2023
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Scott A. Rivkees, Christopher Wendler, Lung-Ji Chang
  • CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
    Publication number: 20190153109
    Abstract: Aspects of the disclosure relate to chimeric antigen receptors (CARs) comprising an antigen binding domain (e.g., anti-TSHR), transmembrane domain (e.g., CD28), and a cytoplasmic domain (e.g., CD27, CD-137, etc.) and a safety mechanism comprising an inducible apoptosis trigger. In some aspects, the disclosure relates to use of the CARs in T cells, compositions, kits and methods for the treatment of thyroid cancers.
    Type: Application
    Filed: April 28, 2017
    Publication date: May 23, 2019
    Applicant: University of Florida Research Foundation, Incorporated
    Inventors: Scott A. Rivkees, Christopher Wendler, Lang-Ji Chang